Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,131.56 -7.70 -0.25%
FTSE 100 6,571.82 -12.35 -0.19%
DAX 9,305.63 -12.19 -0.13%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Gilead Sciences, Halozyme Therapeutics, Santarus, NPS Pharma, and InterMune Under AAAResearchReports.com Microscope



 Gilead Sciences, Halozyme Therapeutics, Santarus, NPS Pharma, and InterMune
                   Under AAAResearchReports.com Microscope

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, July 2, 2013

LONDON, July 2, 2013 /PRNewswire/ --

On Monday, July 1, 2013, shares in biotechnology companies ended mostly
higher, tracking gains in the broader market. All three benchmark indices
edged higher after investors digested better-than-expected U.S. economic data.
The major movers in the industry included Gilead Sciences Inc. (NASDAQ: GILD),
Halozyme Therapeutics Inc. (NASDAQ: HALO), Santarus Inc. (NASDAQ: SNTS), NPS
Pharmaceuticals Inc. (NASDAQ: NPSP), and InterMune Inc. (NASDAQ: ITMN).
AAAResearchReports.com has released full comprehensive research on GILD, HALO,
SNTS, NPSP, and ITMN. These free technical analyses can be downloaded by
signing up at:

http://www.aaaresearchreports.com/register/  

Shares in Gilead Sciences Inc. edged higher on Monday. The company's shares
ended the day 0.75% higher at $51.65 after oscillating between $51.53 and
$52.80. A total of 9.48 million shares were traded which is below the daily
average volume of 11.08 million. In the last three months, Gilead's shares
have gained 7.66%, thus outperforming the S&P 500. A free technical analysis
on GILD available by signing up at:

http://www.AAAResearchReports.com/GILD070213.pdf

Halozyme Therapeutics Inc.'s stock fell sharply on Monday even as the broader
market posted gains. The company's shares traded between $7.36 and $8.15
before finishing the day 3.27% lower at $7.69. A total of 3.60 million shares
were traded which is more than double the daily average volume of 1.45
million. Despite the sharp decline on Monday, Halozyme's shares have gained
18.67% in the last three trading sessions and 43.20% in the last three months.
Register today and access free research on HALO at:

http://www.AAAResearchReports.com/HALO070213.pdf

Shares in Santarus Inc. moved higher on Monday, closing at $21.28, up 1.09%
from its previous closing price. The company's shares fluctuated between
$21.18 and $22.06. A total of 831,052 shares were traded which is below the
daily average volume of 1.30 million. Santarus' shares are currently trading
near their 52-week high of $24.00. The stock is trading above its 50-day and
200-day moving averages. The free report on SNTS can be downloaded by signing
up now at:

http://www.AAAResearchReports.com/SNTS070213.pdf

NPS Pharmaceuticals Inc.'s shares hit an intraday high of $16.13 before
closing the day 5.56% higher at $15.95. A total of 1.74 million shares were
traded which is below the daily average volume of 1.96 million. The company's
shares are currently trading near their 52-week high of $16.47. A free report
on NPSP can be accessed by registering at:

http://www.AAAResearchReports.com/NPSP070213.pdf

Shares in InterMune Inc. edged higher on Monday. The company's shares ended
the day at $9.81, up 1.98%, after oscillating between $9.71 and $10.04. A
total of 1.32 million shares were traded which is above the daily average
volume of 1.15 million. In the last three months, InterMune's shares have
gained 6.75%, hence outperforming the S&P 500. Register with AAA Research
Reports and download research on ITMN for free at:

http://www.AAAResearchReports.com/ITMN070213.pdf

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE AAA Research Reports

Contact: Contact: AAAresearchreports.com, Phone #: +1-(646)-396-9126
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement